



SHIONOGI

Shionogi Inc.

400 Campus Drive, Florham Park,
NJ 07932, USA

Phone: +1-973-966-6900

October 27, 2025

Dear Members of the U.S. Fragile X Community,

We would like to thank you again for your trust and partnership in advancing groundbreaking scientific research in Fragile X syndrome (FXS). Your continued strength, courage, and commitment inspire everything we do.

We would like to share our progress on the **EXPERIENCE clinical development program** (Evaluation of Fragile X **Experience** in **Cognition Expression**) in the U.S. and what to expect next:

- The evaluation phase of two of our clinical trials conducted in the U.S. — EXPERIENCE-301 (in the adult male population, 18-45) and EXPERIENCE-204 (in the adolescent male study population, ages 9-17) — have been completed as planned. We are grateful for the support of the FXS community and investigators to reach this important milestone. Thank you!
- We are now entering the analysis and validation phase. This is an essential process that includes a detailed evaluation of primary and secondary endpoints* as well as measurement tools to ensure the robustness of our findings. We anticipate this phase will take several months.
- In order to ensure that we understand and can interpret the totality of data for zatolmilast in FXS, we will share the results of EXPERIENCE-301 and EXPERIENCE-204 once both sets of results are available.

In the meantime, we would like to assure you that the **open-label extension study EXPERIENCE-302** in the U.S. will continue without any changes or interruptions.

We recognize these research programs could not be completed without your support and participation. We are deeply respectful of the time and effort that this participation entails, and we are fully committed to keeping you informed every step of the way. We continue to believe that together we can make a difference for individuals living with Fragile X and their caregivers and families.

With deep respect and appreciation,

Juan Carlos Gomez, MD, MBA

Chief Medical Officer

Shionogi & Co., Ltd.

If you have any questions about the EXPERIENCE clinical trials in the U.S., please contact medinfo@shionogi.com or 1-800-849-9707. You can also view additional information about EXPERIENCE [here](#) and sign up for updates from Shionogi [here](#).

*An endpoint is an outcome or event in a clinical trial that is measured to determine the effectiveness or safety of a drug being studied.